Ticker
ACRX

Price
0.31
Stock movement down
-0.01 (-4.26%)
Company name
AcelRx Pharmaceuticals Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Drug Manufacturers-Specialty & Generic
Market cap
45.61M
Ent value
134.03M
Price/Sales
51.42
Price/Book
-
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
-72.07%
3 year return
-47.96%
5 year return
-36.28%
10 year return
-20.28%
Last updated: 2022-08-25

DIVIDENDS

ACRX does not pay dividends

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales51.42
Price to Book-
EV to Sales151.10

FINANCIALS

Per share

Loading...
Per share data
Current share count147.12M
EPS (TTM)-0.27
FCF per share (TTM)-0.24

Income statement

Loading...
Income statement data
Revenue (TTM)887.00K
Gross profit (TTM)-2.61M
Operating income (TTM)-35.82M
Net income (TTM)-34.82M
EPS (TTM)-0.27
EPS (1y forward)-0.14

Margins

Loading...
Margins data
Gross margin (TTM)-294.25%
Operating margin (TTM)-4038.11%
Profit margin (TTM)-3925.25%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash21.82M
Net receivables184.00K
Total current assets42.81M
Goodwill0.00
Intangible assets8.82M
Property, plant and equipment0.00
Total assets71.97M
Accounts payable2.71M
Short/Current long term debt16.62M
Total current liabilities17.03M
Total liabilities110.24M
Shareholder's equity-38.27M
Net tangible assets-35.89M

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-29.23M
Capital expenditures (TTM)1.89M
Free cash flow (TTM)-31.12M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-
Return on Assets-48.38%
Return on Invested Capital123.13%
Cash Return on Invested Capital110.06%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open0.31
Daily high0.33
Daily low0.30
Daily Volume1.29M
All-time high13.12
1y analyst estimate4.25
Beta0.60
EPS (TTM)-0.27
Dividend per share-
Ex-div date-
Next earnings date14 Nov 2022

Downside potential

Loading...
Downside potential data
ACRXS&P500
Current price drop from All-time high-97.64%-13.41%
Highest price drop-98.64%-56.47%
Date of highest drop12 May 20229 Mar 2009
Avg drop from high-62.72%-11.38%
Avg time to new high111 days12 days
Max time to new high2290 days1805 days
COMPANY DETAILS
ACRX (AcelRx Pharmaceuticals Inc) company logo
Marketcap
45.61M
Marketcap category
Small-cap
Description
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and 4ARX-03 for mild sedation and pain relief during painful procedures. Its product candidates also include Niyad, a regional anticoagulant for the extracorporeal circuit; and LTX-608, a nafamostat formulation for direct IV infusion being explored as an investigational product for antiviral treatment of COVID, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was incorporated in 2005 and is based in Hayward, California.
Employees
43
Investor relations
-
SEC filings
CEO
Vincent J. Angotti
Country
USA
City
Redwood City
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised set...
September 6, 2022
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised setti...
August 25, 2022
AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of 0% and 5%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
August 11, 2022
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised setti...
August 11, 2022
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised setti...
August 11, 2022
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised setti...
August 10, 2022
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release second quarter financial results after market close on Thursday, August 11, 2022. ...
July 28, 2022
Over the last month the AcelRx Pharmaceuticals, Inc. ( NASDAQ:ACRX ) has been much stronger than before, rebounding by...
July 8, 2022
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised set...
May 20, 2022
The FDA has recently modified the AcelRx Pharmaceuticals Inc's (NASDAQ: ACRX) Dsuvia Risk Evaluation and Mitigation Strategies (REMS) requirements for healthcare setting audits. The Dsuvia REMS progra...
May 19, 2022
Next page